Seres Therapeutics (MCRB) announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place October 19-22 in Atlanta, Georgia. The presentation will include new data describing differences between the SER-155 and placebo groups in the bacterial and fungal organisms causing BSIs, including BSI event clinical outcomes, antibacterial prophylaxis use, and patterns of antimicrobial resistance among the bacterial BSI organisms.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB: